AFFITOME® technology in neurodegenerative diseases: the doubling advantage.

@article{Schneeberger2010AFFITOMETI,
  title={AFFITOME® technology in neurodegenerative diseases: the doubling advantage.},
  author={A. Schneeberger and Markus Mandler and Frank Mattner and Walter Schmidt},
  journal={Human vaccines},
  year={2010},
  volume={6 11},
  pages={948-52}
}
Neurodegenerative diseases are still an area of unmet medical need. This is in contrast to our increasing knowledge on their pathology (e.g., Alzheimer's- (AD), Parkinson's (PD) disease). They are driven by the cerebral accumulation and aggregation of specific proteins (e.g., β-amyloid and hyperphosphorylated tau in the case of AD) in defined brain regions… CONTINUE READING